Clinical features of patients with EGFR mutation-positive non-small cell lung cancer and brain metastases
10.3760/cma.j.cn113030-20200921-00474
- VernacularTitle:EGFR敏感突变非小细胞肺癌脑转移患者临床特征综述
- Author:
Yixiang ZHU
1
;
Ye ZHANG
Author Information
1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院放疗科，北京 100021
- Keywords:
Carcinoma, non-small-cell lung;
Brain metastasis;
Epidermal growth factor receptor;
Clinical feature
- From:
Chinese Journal of Radiation Oncology
2022;31(5):468-472
- CountryChina
- Language:Chinese
-
Abstract:
Advanced non-small cell lung cancer (NSCLC) patients are commonly with brain metastases, leading to poor survival and quality of life. Epidermal growth factor receptor (EGFR) is common sensitive mutation type in NSCLC. Compared with other molecular types, it has different molecular biological characteristics. For patients with brain metastases and EGFR-mutated advanced NSCLC, EGFR-tyrosine kinase inhibitors can prolong overall survival and improve intracranial and extracranial control rate. To understand the characteristics of brain metastases of patients with sensitively EGFR-mutated NSCLC, the incidence, onset time, site, number and size of lesions, symptoms, targeted treatment effect and disease outcomes were reviewed, which can provide reference for interventional timing and local treatment technology selection of local treatment for brain parenchymal metastases.
